Multimodal Diagnostic Assessment of Cerebral Gliomas With FET & FCH PET/CT, and Magnetic Resonance Imaging/Spectroscopy

Impact of Multimodal Diagnostic Assessment of Cerebral Gliomas With F-18-fluoroethyl-L-tyrosine PET/CT, F-18-fluorocholine PET/CT and Magnetic Resonance Imaging and Spectroscopy

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00939315

Acronym

Gliomes-FLP

Enrollment

Registered

2009-07-15

Start date

2009-07-31

Completion date

2016-01-31

Last updated

2016-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Keywords

Glioma, diagnosis, Imaging, Positron emission tomography, Magnetic resonance imaging, Magnetic resonance spectroscopy

Brief summary

The aim of this study is to establish the diagnostic value of O-(2-\[18F\]-fluoroethyl)-L-tyrosine (FET) PET-CT, \[18F\]-fluorocholine (FCH) and magnetic resonance imaging (MRI) combined with magnetic resonance spectroscopy (MRS) in patients with suspected cerebral glioma using neuronavigated biopsies with histopathological analysis as reference.

Detailed description

The objectives of the study are: * To demonstrate if the multimodal approach, combining the morphological aspect of the MRI with the metabolic aspect of the tumor with magnetic resonance spectroscopy (MRS) and O-(2-\[18F\]-fluoroethyl)-L-tyrosine (FET) or 18F\]-fluorocholine (FCH) PET/CTthe FCH allows to improve the location of a active metabolic tumor and its impact on the ideal choice of sampling biopsy. * To underline the differences and similarities between MRS and 18F\]-fluorocholine PET / CT in the assessment of metabolism of the choline. To establish the diagnosis value of both methods, separately and in combination. * To determine which examinations are useful and complementary for the diagnosis and the management of gliomes. FET combined with MRS may be a powerful, widely applicable new method to improve the diagnosis of cerebral gliomas. The extent to which FCH and MRS provide similar information is not known precisely and this study will establish their respective diagnostic value in differentiating tumoral from non-tumoral tissue.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Suspicion of intracerebral glioma on MR * Men of women * Age \>18, no upper limit as long as a biopsy or intervention is foreseen

Exclusion criteria

* Need of rapid intervention in \<2 weeks * Previous neurosurgical intervention (biopsy, shunt, etc.) or any other cerebral treatment

Design outcomes

Primary

Measure	Time frame
Ability of image-guided biopsy using FET, FCH PET/CT and MRS information to target the most representative sites of tumor grade as compared to histopathological examination	On the biopsy day

Countries

Switzerland

Outcome results